Clinical Trial Update: Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (Adrucil) (5-Fluorouracil)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: RECRUITING